Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov 1;276(5):e631.
doi: 10.1097/SLA.0000000000005237. Epub 2022 Jun 28.

Comment on: Upfront Small Bowel Resection for SB-NETs with Synchronous Metastases: A Propensity-score Matched Comparative Population-based Analysis. Increasing Importance in the Era of Peptide Receptor Radionuclide Therapy?

Steven D Scoville  1 , Jordan M Cloyd
Affiliations
Comment

Comment on: Upfront Small Bowel Resection for SB-NETs with Synchronous Metastases: A Propensity-score Matched Comparative Population-based Analysis. Increasing Importance in the Era of Peptide Receptor Radionuclide Therapy?

Steven D Scoville et al. Ann Surg. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Comment on

References

    1. Bennett S, Coburn N, Law C, et al. Upfront small bowel resection for small bowel neuroendocrine tumors with synchronous metastases: a propensityscore matched comparative population-based analysis [published online November 18, 2020]. Ann Surg. doi: 10.1097/SLA.0000000000004647.
    1. Tsilimigras DI, Ntanasis-Stathopoulos I, Kostakis ID, et al. Is resection of primary midgut neuroendocrine tumors in patients with unresectable metastatic liver disease justified? A systematic review and meta-analysis. J Gastrointest Surg. 2019;23:1044–1054.
    1. Almond LM, Hodson J, Ford SJ, et al. Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: a systematic review and metaanalysis. Eur J Surg Oncol. 2017;43:1808–1815.
    1. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–135.
    1. Strosberg JR, Al-Toubah T, Pelle E, et al. Risk of bowel obstruction in patients with mesenteric or peritoneal disease receiving peptide receptor radionuclide therapy. J Nucl Med. 2021;62:69–72.